PMID- 24011160
OWN - NLM
STAT- MEDLINE
DCOM- 20131118
LR  - 20130909
IS  - 1007-8738 (Print)
IS  - 1007-8738 (Linking)
VI  - 29
IP  - 9
DP  - 2013 Sep
TI  - [Clinical value of serum matrix metalloproteinase-3 in evaluating joint 
      destruction and therapeutic effect in rheumatoid arthritis patients].
PG  - 966-9
AB  - OBJECTIVE: To assess the clinical value of serum matrix metalloproteinase-3 
      (MMP-3) in evaluating joint destruction and therapeutic effect in rheumatoid 
      arthritis (RA) patients. METHODS: The study included 109 RA patients and 23 
      healthy volunteers. Serum MMP3, C-reactive protein (CRP), rheumatoid factor (RF) 
      and anti-cyclic citrullinated peptide (CCP) antibody levels were detected. All 
      relevant clinical information of RA patients were recorded. RESULTS: Serum RF, 
      anti-CCP antibodies and MMP3 concentrations in RA patients were markedly higher 
      than those in healthy controls, and serum anti-CCP antibodies and MMP3 levels 
      significantly increased in active RA as compared with those in stable RA 
      (P<0.05). Serum CRP, anti-CCP antibodies and MMP3 levels gradually rose with the 
      progress of joint destruction, but only the increase of serum MMP3 was 
      significant statistically (P<0.05). Serum MMP3 level was found positively 
      correlated with serum CRP or RF levels or joint injury. After the combination 
      treatment of TNF antagonist and methotrexate, DAS28 score, serum CRP, anti-CCP 
      antibodies and MMP3 levels were markedly reduced (P<0.05), and the decrease of 
      MMP3 level was the most obvious. CONCLUSION: Serum MMP3 was a good laboratory 
      index to evaluate the joint injury status and therapeutic effect, which is 
      superior to other traditional and routine laboratory indexes.
FAU - Li, Lixin
AU  - Li L
AD  - Department of Laboratory Medicine, West China Hospital, Sichuan University, 
      Chengdu, China.
FAU - Cai, Bei
AU  - Cai B
FAU - Liao, Jingyu
AU  - Liao J
FAU - Yang, Bin
AU  - Yang B
FAU - Huang, Zhuochun
AU  - Huang Z
FAU - Wang, Lanlan
AU  - Wang L
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
JT  - Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular 
      immunology
JID - 101139110
RN  - 0 (Peptides, Cyclic)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (cyclic citrullinated peptide)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - 9009-79-4 (Rheumatoid Factor)
RN  - EC 3.4.24.17 (MMP3 protein, human)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/drug therapy/*enzymology/pathology
MH  - C-Reactive Protein/analysis
MH  - Female
MH  - Humans
MH  - Male
MH  - Matrix Metalloproteinase 3/*blood
MH  - Middle Aged
MH  - Peptides, Cyclic/immunology
MH  - Rheumatoid Factor/blood
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors
EDAT- 2013/09/10 06:00
MHDA- 2013/11/19 06:00
CRDT- 2013/09/10 06:00
PHST- 2013/09/10 06:00 [entrez]
PHST- 2013/09/10 06:00 [pubmed]
PHST- 2013/11/19 06:00 [medline]
PST - ppublish
SO  - Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2013 Sep;29(9):966-9.